A Real‐World Study of Resectable <scp>NSCLC</scp> Following Neoadjuvant Immunotherapy: Should Postoperative Adjuvant Immunotherapy be Recommended?
Postoperative adjuvant ICI therapy significantly improves EFS in resectable NSCLC patients, especially in those without pCR or MPR. However, its effect on OS remains uncertain. These findings highlight the importance of personalized treatment strategies, with adjuvant ICI offering greater benefits for patients with incomplete pathological responses.
Authors
- Fenghao Sun (ORCID: https://orcid.org/0000-0003-0210-5204)
- Jin Yue (ORCID: https://orcid.org/0000-0001-6802-1973)
- Rongkui Luo (ORCID: https://orcid.org/0000-0002-4118-7225)
- Hari B. Keshava (ORCID: https://orcid.org/0000-0002-9506-2719)
- Hao Yin (ORCID: https://orcid.org/0000-0003-4921-9786)
- Ming Li (ORCID: https://orcid.org/0000-0001-6291-9328)
- Mingxiang Feng (ORCID: https://orcid.org/0000-0003-3061-3943)
Institutions
- Shanghai Medical College of Fudan University (CN)
- Sun Yat-sen University (CN)
- Xuzhou Medical College (CN)
- University of California, Irvine (US)
- Fudan University (CN)
- Huaian First People’s Hospital (CN)
- Zhongshan Hospital of Xiamen University (CN)
- Second People’s Hospital of Huai’an (CN)
- Zhongshan Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Irvine University (US)
Publication Details
- Journal
- Thoracic Cancer
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1111/1759-7714.70195
- Citations
- 1
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- International Association for the Study of Lung Cancer
- National Natural Science Foundation of China
- Natural Science Foundation of Fujian Province
- National Postdoctoral Program for Innovative Talents